Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control.
(2015) In Diabetes & Metabolism 41(6 Suppl 1). p.3-8- Abstract
- Combining insulin with glucagon-like peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors as glucose-lowering therapy for type 2 diabetes is a promising strategy that has gained considerable interest over the past few years. One advantage of this combination is the complementary mechanistic actions of insulin and GLP-1. Insulin increases glucose utilization and retards hepatic glucose production through direct actions in muscle, adipose tissue and the liver. On the other hand, GLP-1 stimulates insulin secretion, inhibits glucagon secretion and retards gastric emptying. Combining these effects results in powerful reductions in both fasting and postprandial glucose through diminished glucose entry into the... (More)
- Combining insulin with glucagon-like peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors as glucose-lowering therapy for type 2 diabetes is a promising strategy that has gained considerable interest over the past few years. One advantage of this combination is the complementary mechanistic actions of insulin and GLP-1. Insulin increases glucose utilization and retards hepatic glucose production through direct actions in muscle, adipose tissue and the liver. On the other hand, GLP-1 stimulates insulin secretion, inhibits glucagon secretion and retards gastric emptying. Combining these effects results in powerful reductions in both fasting and postprandial glucose through diminished glucose entry into the bloodstream after food consumption, reduced hepatic production of glucose and increased glucose utilization. In addition, GLP-1 receptor agonists induce satiety, leading to decreases in food intakes and body weight, thereby preventing the weight gain often seen with insulin therapy. Clinical trials have verified that these physiological effects as a result of combining insulin with GLP-1 receptor agonists or DPP-4 inhibitors can indeed result in improved glycaemia, with limited risks of hypoglycaemia and weight gain. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8577522
- author
- Ahrén, Bo LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Diabetes & Metabolism
- volume
- 41
- issue
- 6 Suppl 1
- pages
- 3 - 8
- publisher
- Elsevier Masson SAS
- external identifiers
-
- pmid:26774018
- wos:000368215500002
- scopus:84953226707
- ISSN
- 1878-1780
- DOI
- 10.1016/S1262-3636(16)30002-7
- language
- English
- LU publication?
- yes
- id
- 2da0949e-7a2e-4bb0-bfac-d021949adb2d (old id 8577522)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26774018?dopt=Abstract
- date added to LUP
- 2016-04-01 09:57:00
- date last changed
- 2024-01-06 03:57:46
@article{2da0949e-7a2e-4bb0-bfac-d021949adb2d,
abstract = {{Combining insulin with glucagon-like peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors as glucose-lowering therapy for type 2 diabetes is a promising strategy that has gained considerable interest over the past few years. One advantage of this combination is the complementary mechanistic actions of insulin and GLP-1. Insulin increases glucose utilization and retards hepatic glucose production through direct actions in muscle, adipose tissue and the liver. On the other hand, GLP-1 stimulates insulin secretion, inhibits glucagon secretion and retards gastric emptying. Combining these effects results in powerful reductions in both fasting and postprandial glucose through diminished glucose entry into the bloodstream after food consumption, reduced hepatic production of glucose and increased glucose utilization. In addition, GLP-1 receptor agonists induce satiety, leading to decreases in food intakes and body weight, thereby preventing the weight gain often seen with insulin therapy. Clinical trials have verified that these physiological effects as a result of combining insulin with GLP-1 receptor agonists or DPP-4 inhibitors can indeed result in improved glycaemia, with limited risks of hypoglycaemia and weight gain.}},
author = {{Ahrén, Bo}},
issn = {{1878-1780}},
language = {{eng}},
number = {{6 Suppl 1}},
pages = {{3--8}},
publisher = {{Elsevier Masson SAS}},
series = {{Diabetes & Metabolism}},
title = {{Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control.}},
url = {{http://dx.doi.org/10.1016/S1262-3636(16)30002-7}},
doi = {{10.1016/S1262-3636(16)30002-7}},
volume = {{41}},
year = {{2015}},
}